Contact Us
+1877- DYNAMILL (3962 6455)
Our Location
16W285 83rd St. STE D-1 Burr Ridge, IL 60527
info@dynamillcro.com
Social Network
Close
A diagnostic CRO should understand that diagnostic studies are not the same as drug trials. The right diagnostic clinical trial CRO should help sponsors design FDA-ready protocols, select appropriate sites, manage comparator testing, protect biospecimen integrity, oversee data quality, and generate evidence that supports regulatory and commercial decision-making.
For diagnostic companies, the best CRO partner is not simply the largest vendor. It is the CRO that understands diagnostic accuracy, intended use, specimen workflows, comparator strategy, regulatory pathway requirements, and the operational realities of running diagnostic clinical studies.
Diagnostic development depends on evidence. Whether a sponsor is developing a molecular diagnostic, point-of-care test, companion diagnostic, AI-enabled diagnostic tool, or medical device diagnostic platform, the clinical study must show how the test performs in the intended population and use setting.
That is why choosing a diagnostic CRO is such an important decision.
A general CRO may be strong in drug development but still miss the unique operational risks of diagnostic studies. Diagnostic studies often involve specific sample types, time-sensitive processing, comparator testing, laboratory coordination, site workflow training, and strict data traceability. A small operational error can affect the quality of the evidence.
A specialized diagnostic CRO brings study design, site management, monitoring, data oversight, and regulatory readiness together from the beginning.
Diagnostic clinical trials are different because the evidence is usually tied to the test’s intended use and performance.
A diagnostic study may need to answer questions such as:
These questions affect protocol design, site selection, sample size, comparator strategy, monitoring plans, and final reporting.
This is why diagnostic sponsors should involve operations and regulatory strategy early, ideally before the protocol is finalized.
A strong diagnostic CRO should understand how to design studies around intended use, target population, specimen type, disease prevalence, comparator method, and performance endpoints.
For example, the study design for a point-of-care test used in urgent care is very different from a molecular assay performed in a central laboratory. A companion diagnostic study may have different requirements from a screening test or rule-out test.
The CRO should be able to help define:
Intended use population
Inclusion and exclusion criteria
Specimen collection requirements
Comparator or reference standard
Performance endpoints
Statistical considerations
Site workflow feasibility
Monitoring and data review strategy
The goal is not only to conduct the study. The goal is to produce evidence that is usable.
A diagnostic CRO does not replace regulatory counsel, but it should understand how clinical evidence connects to FDA strategy.
Depending on the device, a sponsor may be considering a 510(k), De Novo, PMA, IDE, CLIA waiver, or other regulatory route. Each pathway can influence the type of evidence needed.
For example, a 510(k) often focuses on substantial equivalence to a predicate device, while a De Novo pathway may apply when there is no legally marketed predicate. PMA is generally associated with higher-risk devices and more rigorous evidence expectations.
A CRO that understands these pathways can help sponsors avoid a common mistake: designing a study that is operationally complete but not aligned with regulatory expectations.
Site selection can make or break a diagnostic study.
The right sites must have access to the intended patient population, the correct clinical workflow, trained staff, specimen handling capability, and the ability to complete required study procedures without creating unnecessary deviations.
For diagnostic clinical studies, site feasibility should look beyond enrollment numbers. It should also assess:
Patient population match
Specimen collection capacity
Laboratory workflow
Comparator testing availability
Staff training needs
Data entry capability
IRB and contracting timelines
History of protocol compliance
A strong diagnostic trial management partner should help sponsors select sites that can execute the study correctly, not just enroll quickly.
Comparator testing is one of the most important areas in diagnostic clinical research.
If the comparator method is poorly selected, inconsistently applied, delayed, or not documented properly, the entire study can be weakened. Diagnostic sponsors should ask CROs how they manage comparator strategy and oversight.
Important questions include:
What comparator or reference method will be used?
Is the comparator clinically and scientifically appropriate?
Who will perform comparator testing?
How will specimen transfer be documented?
How will discordant results be managed?
How will missing or invalid comparator results be handled?
A diagnostic CRO should be able to coordinate between clinical sites, laboratories, central labs, and the sponsor to keep comparator testing consistent and traceable.
Specimens are central to diagnostic evidence. A study can be compromised by the wrong sample type, delayed processing, temperature excursions, incomplete labels, or unclear rejection criteria.
A diagnostic CRO should help define and manage:
Sample type and volume
Collection procedure
Labeling requirements
Storage conditions
Shipping procedures
Temperature monitoring
Chain-of-custody documentation
Rejection criteria
Sample reconciliation
Specimen integrity protects evidence integrity. This is especially important for IVD clinical studies, molecular diagnostics, infectious disease testing, and point-of-care diagnostics.
Diagnostic studies need clean, reviewable, and traceable data.
A good diagnostics CRO should support structured data capture, query management, monitoring, and real-time study visibility. Sponsors should be able to see enrollment progress, site performance, protocol deviations, specimen status, and data quality trends without waiting until the end of the study.
Real-time dashboards and proactive monitoring can help identify issues early, such as:
Missing comparator results
Delayed specimen processing
Site-level deviation trends
Incomplete source documentation
Unexpected screen failure patterns
Data entry delays
This kind of oversight supports faster decisions and stronger submission readiness.
Choosing a CRO Too Late
Many sponsors involve operations after the protocol is nearly final. This can create feasibility issues, budget gaps, site workflow problems, and avoidable amendments.
Treating Diagnostic Studies Like Drug Trials
Diagnostic evidence depends heavily on test performance, specimen handling, comparator methods, and intended use. These details require specialized planning.
Waiting Too Long to Review Data
Data quality should be reviewed during the study, not only at database lock.
Weak Site Training
Even good sites need diagnostic-specific training. Staff must understand sample handling, device workflow, documentation, and result interpretation requirements.
Underestimating Comparator Complexity
Comparator strategy should be built into the study design early. If the comparator process is unclear, the data may become difficult to interpret.
Dynamill Research is built for diagnostic and medical device innovation. As a diagnostic CRO, Dynamill supports sponsors with purpose-built clinical study execution, lean oversight, transparent communication, and regulatory-focused operations.
Dynamill can support diagnostic companies across:
For diagnostic sponsors, the right CRO partner should make the study more predictable, more transparent, and more submission-ready.
Contact Us
+1877- DYNAMILL (3962 6455)
Our Location
16W285 83rd St. STE D-1 Burr Ridge, IL 60527
info@dynamillcro.com
Social Network
A diagnostic CRO is a clinical research organization that specializes in clinical studies for diagnostic tests, IVDs, medical devices, point-of-care tests, molecular diagnostics, and related technologies.
A diagnostic CRO focuses on intended use, test performance, comparator testing, specimen handling, site workflow, and diagnostic evidence generation. Pharma CROs are usually focused on drug safety, efficacy, dosing, and therapeutic outcomes.
A diagnostic sponsor should involve a CRO before the protocol is finalized. Early CRO involvement helps align study design, site feasibility, comparator testing, budget, and operational planning.
A diagnostic CRO can help with study design, site selection, IRB coordination, monitoring, data management, comparator oversight, biospecimen logistics, and regulatory-ready documentation.
Comparator testing helps show how the investigational diagnostic performs against an accepted reference method, predicate, or clinical standard. Poor comparator planning can weaken the evidence package.